cyc 202 has been researched along with defactinib in 2 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (defactinib) | Trials (defactinib) | Recent Studies (post-2010) (defactinib) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 41 | 5 | 41 |
| Protein | Taxonomy | cyc 202 (IC50) | defactinib (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0282 | |
| High affinity nerve growth factor receptor | Homo sapiens (human) | 0.0413 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.129 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.2732 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.1149 | |
| Mitogen-activated protein kinase kinase kinase 9 | Homo sapiens (human) | 0.0753 | |
| Focal adhesion kinase 1 | Homo sapiens (human) | 0.0014 | |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | 0.0293 | |
| NT-3 growth factor receptor | Homo sapiens (human) | 0.0578 | |
| BDNF/NT-3 growth factors receptor | Homo sapiens (human) | 0.0549 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Sakai, M; Yoshimura, R | 1 |
2 other study(ies) available for cyc 202 and defactinib
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Mechanotransduction-Targeting Drugs Attenuate Stiffness-Induced Hepatic Stellate Cell Activation in Vitro.
Topics: Actins; Adenosine Triphosphate; Animals; Benzamides; Cells, Cultured; Colchicine; Collagen Type I; Hepatic Stellate Cells; Imidazoles; Integrins; Male; Mechanotransduction, Cellular; Paclitaxel; Piperazines; Pyrazines; Quinoxalines; Rats, Sprague-Dawley; Roscovitine; Sulfonamides; Transforming Growth Factor beta; Tubulin Modulators | 2021 |